Dr. Werner Kroll, Senior Vice President, Research & Development of QuidelOrtho Corporation, oversees R&D innovation for the company’s immunoassay and molecular products, leading groundbreaking developments from initial concept to manufacturability with the goal of improving human health globally.

Dr. Kroll has over three decades of industry experience, holding multiple leadership positions in research and development for major companies in the diagnostics space.

Dr. Kroll served as Senior Vice President, Research & Development of Quidel Corp. from 2014 to 2022, where he facilitated the development of countless industry-defining immunoassay and molecular products. Prior to joining Quidel, Dr. Kroll was Vice President and Global Head of Research and Innovation for Novartis Molecular Diagnostics/Codiagnostics. He has also held senior positions at Novartis Pharmaceuticals, Bayer Diagnostics, Bayer Pharmaceuticals, and AGFA. In addition, Dr. Kroll serves on the board of directors of the European Personalised Medicine Association (EPEMED).

Dr. Kroll received his Ph.D. in Physiological Chemistry from the University of Marburg.